Read, S.H.; Kutikova, L.; Gusto, G.; Kapnang, R.; Quignot, N.; Khachatryan, A.; El Guerche-Séblain, C.; Petit, V.; Fix, J.; Rousculp, M.D.;
et al. Real-World Utilization of the Novavax Adjuvanted Recombinant Protein COVID-19 Vaccine in France During the 2022–2024 Period. Vaccines 2026, 14, 790.
https://doi.org/10.3390/vaccines14090790
AMA Style
Read SH, Kutikova L, Gusto G, Kapnang R, Quignot N, Khachatryan A, El Guerche-Séblain C, Petit V, Fix J, Rousculp MD,
et al. Real-World Utilization of the Novavax Adjuvanted Recombinant Protein COVID-19 Vaccine in France During the 2022–2024 Period. Vaccines. 2026; 14(9):790.
https://doi.org/10.3390/vaccines14090790
Chicago/Turabian Style
Read, Stephanie H., Lucie Kutikova, Gaelle Gusto, Raissa Kapnang, Nadia Quignot, Artak Khachatryan, Clotilde El Guerche-Séblain, Vincent Petit, Jonathan Fix, Matthew D. Rousculp,
and et al. 2026. "Real-World Utilization of the Novavax Adjuvanted Recombinant Protein COVID-19 Vaccine in France During the 2022–2024 Period" Vaccines 14, no. 9: 790.
https://doi.org/10.3390/vaccines14090790
APA Style
Read, S. H., Kutikova, L., Gusto, G., Kapnang, R., Quignot, N., Khachatryan, A., El Guerche-Séblain, C., Petit, V., Fix, J., Rousculp, M. D., Janssen, C., & Launay, O.
(2026). Real-World Utilization of the Novavax Adjuvanted Recombinant Protein COVID-19 Vaccine in France During the 2022–2024 Period. Vaccines, 14(9), 790.
https://doi.org/10.3390/vaccines14090790